Chung Yin Kong

Trends in Esophageal Adenocarcinoma Incidence and Mortality

Over the past several decades, the incidence of esophageal adenocarcinoma (EAC) has rapidly increased. The purpose of this analysis was to examine temporal trends in EAC incidence and mortality within the US population and, in addition, to explore these trends within subgroups of the population.

Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States

Introduction: A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level. Methods: Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained (

Original Articles: Diagnostic Tests/StagingCost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States

/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4–30% 1-year abstinence); and combined programs. Results: Annual screening of current and former smokers aged 50 to 74 years costs between

Impact of Reduced Tobacco Smoking on Lung Cancer Mortality in the United States During 1975–2000

126,000 and

The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus

169,000/QALY (minimum 20 pack-years of smoking) or

Estimating Long-term Effectiveness of Lung Cancer Screening in the Mayo CT Screening Study

110,000 and

The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data.

166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below

Monte Carlo study of adsorption of a polyelectrolyte onto charged surfaces

75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs

Calibration methods used in cancer simulation models and suggested reporting guidelines.

130,500 to

Annual Screening Strategies in BRCA1 and BRCA2 Gene Mutation Carriers: A Comparative Effectiveness Analysis

159,700/QALY, when compared with annual stand-alone cessation. Conclusions: The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.